Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	-11.61	-12.85	-42.43	-9.82	-19.68	-25.51
Depreciation & Amortization	0.01	0.01	0.12	-	0.92	2.32
Other Amortization	-	-	-	-	0.26	-
Loss (Gain) From Sale of Assets	-0.01	-0.06	-	-	-	-
Asset Writedown & Restructuring Costs	0.02	0.04	33.95	0.25	5.7	-
Stock-Based Compensation	1	0.91	1.81	1.34	1.17	1.95
Other Operating Activities	-3.53	0.9	-9.55	-6.22	3.24	1.51
Change in Accounts Receivable	0.42	0.08	-0.3	-0.02	0.06	0.58
Change in Accounts Payable	1.32	-1.65	0.41	-2.39	-6.7	-3.39
Change in Other Net Operating Assets	0.57	0.29	0.07	-0.38	0.7	-0.41
Operating Cash Flow	-11.82	-12.33	-15.91	-17.23	-14.32	-22.95
Capital Expenditures	-0.02	-0.02	-0.02	-	-0.07	-0.32
Sale of Property, Plant & Equipment	0	0.11	-	-	-	-
Investment in Securities	-	0.02	13.17	-3.52	-9.79	8.46
Investing Cash Flow	-0.02	0.1	13.15	-3.52	-9.86	8.14
Short-Term Debt Repaid	-	-	-	-	-	-1.56
Total Debt Repaid	-	-	-	-	-	-1.56
Net Debt Issued (Repaid)	-	-	-	-	-	-1.56
Issuance of Common Stock	-	7.36	0.3	-	59.63	14.73
Other Financing Activities	-	-	-	-	-0.14	0.01
Financing Cash Flow	-	7.36	0.3	-	59.49	13.18
Foreign Exchange Rate Adjustments	-	-	-0.01	0.15	1.39	-1
Net Cash Flow	-11.84	-4.87	-2.46	-20.6	36.7	-2.63
Free Cash Flow	-11.84	-12.36	-15.93	-17.23	-14.39	-23.27
Free Cash Flow Margin	-	-	-	-	-7340.82%	-
Free Cash Flow Per Share	-1.03	-1.30	-2.14	-2.81	-5.82	-13.21
Levered Free Cash Flow	-7.16	-7.4	-9.06	-4.57	-7.81	-18.48
Unlevered Free Cash Flow	-7.16	-7.4	-9.06	-4.57	-7.91	-18.32
Change in Net Working Capital	-2.31	1.26	-0.4	-1.68	3.25	7

Source: S&P Capital IQ. Standard template. Financial Sources.